Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Abituzumab × Gastrointestinal × Clear all

Phase

Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 1

Interventions

Gemcitabine 151 Oxaliplatin 122 Fluorouracil 107 Capecitabine 103 pembrolizumab 91 Bevacizumab 79 Leucovorin 74 Irinotecan 72 Nivolumab 69 130-nm albumin-bound paclitaxel 67 Paclitaxel 62 Cisplatin 62 Cetuximab 59 Cyclophosphamide 45 Albumin-Bound Paclitaxel 45 Radiotherapy 39 Docetaxel 36 durvalumab 33 Sorafenib 32 Taxes 29 Carboplatin 27 tislelizumab 24 fludarabine 24 atezolizumab 24 Drug Therapy 24 Folfox protocol 22 regorafenib 20 lenvatinib 19 sintilimab 18 camrelizumab 18

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01008475 2016-03-30

POSEIDON

Merck KGaA, Darmstadt, Germany

Phase 1/2 Completed

232 enrolled 20 charts

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡